Abstract | PURPOSE: PATIENTS AND METHODS: Between January 1999 and September 2004, eight patients with histologically proven MM of the nasal cavity and paranasal sinuses were treated with IMRT. A median dose of 66 Gy was applied to the macroscopic tumor (gross tumor volume [GTV]; range, 60-68 Gy) as an integrated boost and a median dose of 59 Gy (range, 54-64 Gy) to the clinical target volume (CTV) with IMRT. RESULTS: Treatment-related toxicity was very mild in most patients. Overall survival was 80% at 5 years. Calculated from treatment with IMRT as primary radiotherapy, survival was 100% at 1 year and 75% at 3 years. After IMRT, local progression-free survival was 71.4% at 1 year and 57.1% at 3 years, respectively. Distant progression-free survival after IMRT was 57.1% at 1 year and 28.6% at 3 years. CONCLUSION: Local dose escalation with IMRT yields good treatment results with respect to local and distant tumor control as well as survival, while treatment-related toxicity can be minimized.
|
Authors | Stephanie E Combs, Stephan Konkel, Christoph Thilmann, Jürgen Debus, Daniela Schulz-Ertner |
Journal | Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
(Strahlenther Onkol)
Vol. 183
Issue 2
Pg. 63-8
(Feb 2007)
ISSN: 1439-099X [Electronic] Germany |
PMID | 17294109
(Publication Type: Clinical Trial, Journal Article)
|
Topics |
- Adolescent
- Adult
- Aged
- Dose Fractionation, Radiation
- Female
- Humans
- Male
- Melanoma
(radiotherapy)
- Middle Aged
- Nasal Cavity
(radiation effects)
- Nasal Mucosa
(radiation effects)
- Paranasal Sinus Neoplasms
(radiotherapy)
- Radiation Injuries
(etiology, prevention & control)
- Radiation Protection
(methods)
- Radiotherapy, Conformal
(adverse effects, methods)
- Survival Analysis
- Survival Rate
- Treatment Outcome
|